Diurnal Group flow of regulatory approvals excites shareholders (Analyst Interview)

Diurnal Group plc (LON:DNL) is the topic of conversation when Hardman & Co Analyst Martin Hall joins DirectorsTalk. Martin talks us through some of the more interesting newsflow items, expands on the significance of the US partnering deal with Eton, the more recent Alkindi approvals, what we can expect from 2020/21 and shares his thoughts on share price movement.

Diurnal Group is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an “Adrenal Franchise”. Alkindi® is currently being rolled out throughout Europe, and recent approvals in Israel and Australia will open up more markets. Approaching next month, all attention will turn towards the US, where the PDUFA date has been set for 29 September. Upfront cash from the US commercial deal with Eton Pharmaceuticals (Eton), together with the recent Placing, has strengthened the balance sheet.

You might also enjoy reading  Pantheon International 35 years’ outperformance, positioned for resilient, long-term secular growth (Analyst VIDEO)
Find more news, interviews, share price & company profile here for:
Hardman & Co

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp